The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

9月7日至9月11日（奥地利维也纳时间），第34届欧洲呼吸学会（ERS 2024）年会盛大召开。来自全球各地的呼吸领域顶尖学者齐聚维也纳，为广大呼吸病学者带来了一场精彩的学术盛宴！

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

AstraZeneca’s FASENRA ® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids Dr. Michael Wechsler, Professor ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

AstraZeneca’s Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune-mediated vasculitis that can be fatal ...

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.